China Universal Asset Management Company’s Adaptimmune Therapeutics ADAP Stock Holding History

China Universal Asset Management Company’s Portfolio ADAP Stock Details ADAP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-5,285	Closed	-$4.12K	–	429
2023 Q3	$4.12K	Buy	5,285 +3,367	+176%	+$2.83K	﹤0.01%	401
2023 Q2	$1.77K	Sell	1,918 -52	-3%	-$62	﹤0.01%	433
2023 Q1	$2.15K	Buy	1,970 +501	+34%	+$776	﹤0.01%	429
2022 Q4	$2.15K	Buy	1,469 +124	+9%	+$201	﹤0.01%	368
2022 Q3	$1K	Buy	+1,345	New	+$2.47K	﹤0.01%	377

Other funds holding ADAP

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

China Universal Asset Management Company's ADAP Position: Q4 2023 in Review

China Universal Asset Management Company sold out of Adaptimmune Therapeutics (ADAP) in Q4 2023, closing a stake of 5,285 shares — an estimated $4.12K sold.

China Universal Asset Management Company first reported a position in ADAP in Q3 2022 and held it in 5 quarters. The position peaked at $4.12K in Q3 2023. 79 funds tracked by Wall St. Rank hold ADAP as of Q4 2023.

China Universal Asset Management Company reported no remaining Adaptimmune Therapeutics position as of Q4 2023 after selling out during the quarter.
China Universal Asset Management Company sold 5,285 Adaptimmune Therapeutics shares in Q4 2023, an estimated $4.12K.
China Universal Asset Management Company first reported a position in Adaptimmune Therapeutics in Q3 2022 and held it in 5 quarters.
China Universal Asset Management Company's Adaptimmune Therapeutics position peaked at $4.12K in Q3 2023.
79 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2023.

Based on China Universal Asset Management Company's 13F filing for Q4 2023, filed 24 Jan 2024.